跳到正文
原文
Nature 健康护理主题·· 2026-10-09精选AI 评分66

GMALL B-ALL/NHL 2002方案治疗高级别B细胞淋巴瘤,单中心53例6年PFS为72%

The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma

AI 导读

单中心53例高级别B细胞淋巴瘤患者接受GMALL B-ALL/NHL 2002强化方案治疗,结束治疗时代谢完全缓解率为79.2%,6年PFS为72%、OS为76%。6年PFS在HGBCL NOS患者中为83%、双打击淋巴瘤为49%,55岁以上患者为61%、55岁及以下为82%。作者指出该单中心回顾性研究无法证明其优于CODOX-M/IVAC或DA-EPOCH-R,双打击淋巴瘤仍是主要难点。

推荐理由

单中心53例回顾性数据给出该强化方案在高级别B细胞淋巴瘤的6年PFS与OS分层结果,可与现有强化方案对照参考。

正文

To the editor,

The front-line treatment of High-Grade B Cell lymphoma (HGBCL) still represents a significant clinical challenge, without a consensus on the current standard of care [1, 2]. Prospective trials have more often pooled HGBCL with Diffuse Large B-Cell Lymphomas (DLBCL) thus clinical practice recommendations rely mainly on subset analysis and cohort extrapolations. Current treatment approaches for HGBCL include intensified chemotherapy programs such as CODOX-M-IVAC or R-DA EPOCH with survival rates ranging from 60% to 90%. However, a comparative analysis of trials is difficult due to different inclusion criteria and the small numbers of patients included [3,4,5,6].

The GMALL B ALL/NHL 2002 is an intensive chemotherapy protocol that yielded high rates of complete and durable responses in other aggressive lymphoid-histology, such as Burkitt Lymphoma (BL) [7, 8].

From February 2011 to December 2023, we adopted the GMALL B-ALL/NHL2002 protocol (Clinical trial.gov NCT03131531) at our institution for the treatment of patients with HGBCL, NOS and Double Hit Lymphoma (DHL). All patients had a proven histological diagnosis on lymph node or other tissue biopsies, according to the WHO criteria. Fluorescence in situ hybridization (FISH) for MYC, BCL2, and BCL6 rearrangement was performed.

The clinical protocol with dose reduction according to age (over/under 55 years old) has been previously published (see Supplementary Table S1) [7]. Patients with stage III–IV disease received six courses (A1-B1-C1-A2-B2-C2) every 21 days and 8 Rituximab doses, while stage I–II patients received four cycles (A1-B1-C1-A2) every 21 days and 6 Rituximab doses. Patients aged up to 55 years received the full dose program with courses A–C, while patients over 55 years received courses A and B only, with reduced drug doses. Fit patients older than 55 years of age could be treated with the full intensity protocol if deemed appropriate by the responsible physician. A lumbar puncture with triple intrathecal therapy (TIT) was performed in all patients during cycle A and B. In case of central nervous system (CNS) involvement, TIT was repeated until three negative results were obtained.

Treatment response was evaluated according to Lugano criteria; a CT and a PET scan were performed at diagnosis, after 2 cycles and 4/6 weeks after end of treatment (EOT).

A total of 53 patients with HGBCL were treated with the GMALL B ALL/NHL 2002 protocol at our institution. The diagnosis was HGBCL, NOS in 34 patients (64,1%), while 19 patients were classified as DHL (35.9%) according to WHO 2022. The median age was 56 years (21-75), and 50.9% of patients were >55 years old (n = 27). Clinical characteristics of treated patients are presented in Table 1.

Table 1 Demographic characteristics of the in study population and by histology.

Full size table

Thirty-six patients received the full intensity regimen (including 10 patients aged >55 years) while 17 received the protocol-based, age-reduced schedule. Due to toxic adverse events, the dose intensity was reduced in 5 patients (9.4%), of whom 4 were younger than 55 years.

The median intercycle time (MIT) between chemotherapy courses, calculated from day 1 of the first chemotherapy cycle to day 1 of the last received chemotherapy block, was 29 days (range, 21–60 days), no matter the different histology (DHL: median 30 days, range 24-60 days; HGBCL NOS median 28.7 days, range 21–46; p = 0.42) or age (≤55 years: median 29.7 days, range 23.4–60 days; >55 years: median 28.6 days, range 21–46.6; p = 0.65).

At EOT, a metabolic complete response (CR) was achieved in 42 (79,2%) patients, a partial response (PR) in 7 patients (13,2%). Four patients did not show any meaningful clinical response (see Supplementary Table S2). Three CR patients developed a CNS relapse occurring within 3 months from CR achievement. In two patients (a DHL and a HGBCL-NOS) systemic chemotherapy with high dose methotrexate and cytarabine was given. A third patient (with DHL) was treated with whole brain radiotherapy (40 Gy). These 3 patients rapidly progressed and died.

At 6 years, the PFS for the entire population is 72%, (83% HGBCL NOS; 49% DHL). The 6-year PFS for patients older than 55 years is 61% compared to 82% for those under 55 years old (see Fig. 1). Of note, among patients older than 55 years, the PFS is higher among those who received full course therapy than those who received the dose-reduced schedule (3-year PFS 88% vs 68% respectively). PFS and DFS analysis are reported in Supplementary Figs. S1 and S2. After a median follow-up of 4.5 years (range, 0.4-13 years), 42 patients (75%) are alive. Overall, 11 patients died: 9 patients due to refractory or relapsed disease, while two patients died in CR. One patient developed therapy-related myelodysplastic syndrome, which progressed rapidly and ultimately resulted in death. The second patient had a concomitant psychiatric comorbidity (major depression), which was the primary reason for discontinuing regular follow-up. The family informed us about the death which happened in the absence of any documented lymphoma relapse

Fig. 1: OS and PFS Kaplan Maier curves.

A PFS in the entire population; B OS in the entire population; C PFS according to age; D OS according to age; E PFS according to histology group; F OS according to histology group.

A visual representation of the outcomes is reported in Supplementary Fig. S3. The 6-year Overall Survival (OS) is 76%, 86% for HGBCL NOS patients and 56% for DHL patients (see Fig. 1). When stratified by treatment response, the OS at 6 years is 87% for patients in CR, and 57% for patients with PR (see Supplementary Fig. S1). By age, the 6-year OS is 92% and 61% for patients younger or older than 55 years, respectively (see Supplementary Fig. S1). For patients older than 55 years the OS is better for those who received a full course therapy (3-year OS 88% vs 68% respectively). Six-year PFS, OS and DFS rates according to histology and age are summarized in Supplementary Table S3.

Nearly 50% of patients (n = 25) experienced adverse reactions to therapy. Febrile neutropenia occurred in 22.6% of patients (n = 12), sepsis in 7.5% of cases (n = 4), mucositis in 16.9% of patients (n = 9). Three patients (n = 3) experienced hepatic toxicity after the first induction cycle (A1), which was resolved with treatment delay and supportive care. No patient died during treatment due to protocol adverse events directly related to chemotherapy. Of note, one patient (1.8%) developed secondary myelodysplasia and died for this reason. A longer follow up is mandatory to monitor the impact of the protocol GMALL ALL/NHL 2002 on the bone marrow stem cell reservoir.

By univariate analysis, the probability of achieving a response was lower in patients with ECOG 2-4 (OR 0.18 (0.04–0.71); p = 0.017) and with high LDH levels (OR 0.92 (0.85–0.97); p = 0.007), while other variables such as histology, age, stage, bulky mass or MIT did not have an impact (see Supplementary Table S4). PFS was lower for DHL histology (HR 0.28 (0.09–0.86), p = 0.026), high LDH levels (HR 1.09 (1.04–1.14), p = 0.0001), and low lymphocyte-monocyte (LM) ratio (HR 1.33 (1.05–1.69), p = 0.019) [9]. An age older than 55 years (HR 4.75, 1.02-22.01) (p = 0.047), a poor ECOG performance status (2-4) (HR 3.96, 1.16–13.54), (p = 0.028) and DHL histology (HR 0.25, (0.07-0.85), p = 0.027) were risk factors for poor survival. Bulky disease, Ann Arbor stage, B symptoms, HIV status, the IPI score, and extra nodal disease did not significantly impact PFS or OS (see Supplementary Table S4). At multivariate analysis, LDH level was the only variable with a significant impact on PFS and OS (HR 1.06 (1.01-1.12), P = 0.0224 and 1.08 (1.03-1.13), p = 0.0008 respectively) (see Supplementary Information, Table S5).

Our study confirms the efficacy of the GMALL B-ALL/NHL2002 protocol for the treatment of adult patients with HGBCL, NOS and DHL and proved feasible even in patients above the age of 55. When compared to other intensive regimens, both in prospective and retrospective series, the dose-dense GMALL protocol we adopted shows similar clinical outcomes (see Supplementary Table S6) [3,4,5,6, 10,11,12]. We have no data to claim superiority of the GMALL program over the CODOX-M/IVAC or the dose-adjusted EPOCH-R. However, this latter program, which offers the benefit to be potentially administered in an outpatient setting, may be less feasible in patients at high risk of CNS recurrence and those with evidence of CNS involvement at diagnosis. Indeed, for patients treated with dose-adjusted EPOCH-R, the invasive positioning of an Ommaya device has been often required to allow an adequate administration of CNS active treatments.

Despite its potential academic interest, a randomized trial comparing these intensive regimens would be very difficult to design and conduct. The main challenges would include defining an appropriate primary endpoint; calculating a feasible sample size; and addressing the limited novelty of such a study. More importantly, any future clinical trial in this setting should build on and align with existing chemotherapy backbones, while incorporating one or more new agents, such as innovative antibodies or BCL-2 inhibitors. A point of strength of our study is the large number of patients with HGBCL, NOS and DHL who received this intensified, Burkitt-like, chemotherapy program. An additional point is that we did not pool our patients with other aggressive B-cell lymphoma entities, such as Burkitt Lymphoma or MYC-rearranged Lymphomas, as often happened in other retrospective series.

We must acknowledge that the PFS of at least one third of this aggressive subgroup of NHL patients remains largely unsatisfactory, particularly for DHL. The biology of DHL confers an intrinsic risk of chemoimmunotherapy resistance, and alternative strategies with the integration of cellular therapy and bispecific antibodies in first line regimens are needed to treat these patients [13,14,15].

In line with other studies, this dose-intense approach should be wisely adapted to older patients. The need of dose reduction in patients older than 55 years represents a limit in the delivery of GMALL protocol both in terms of 6-year PFS and OS. For this subgroup of patients, the benefit gained by novel immunotherapy is expected to be the most significant.

Our study has additional limitations inherent to its retrospective design. A selection bias is possible, for patients fit for intensive chemotherapy and histology, FISH, and imaging (CT and PET) were not independently reviewed.

In conclusion, in this single-center experience, the GMALL B ALL/NHL 2002 protocol achieved good response rates and survival in a well-defined cohort of HGBCL patients, offering a feasible therapeutic option for this hard-to-treat niche.

Data availability

The authors are willing to make available deidentified datasets and protocol to other investigators upon reasonable requests for research purposes. For original data, please contact [Dr Silvia Ferrari, s.ferrari@asst-pg23.it].

References

  1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. https://doi.org/10.1038/s41375-022-01620-2.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Olszewski AJ, Kurt H, Evens AM. Defining and treating high-grade B-cell lymphoma, NOS. Blood. 2022;136:2125–32. https://doi.org/10.1182/BLOOD.2019000962.

    Article  Google Scholar 

  3. McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31:1251–9. https://doi.org/10.1016/j.annonc.2020.05.016.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-Adjusted EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab) in Untreated Aggressive Diffuse Large B-Cell Lymphoma with MYC Rearrangement: A Prospective, Multicentre, Single-Arm Phase 2 Study. Lancet Haematol. 2018;5:e609–e617. https://doi.org/10.1016/S2352-3026(18)30177-7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Atallah-Yunes SA, Rees MJ, Witzig TE, Habermann TM, Munoz J, Iqbal M, et al. CODOX-M/IVAC-R versus DA-EPOCH-R in double-hit/triple-hit lymphoma patients aged 60 years or under. Haematologica. 2025;110:448–56. https://doi.org/10.3324/haematol.2024.286168.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, et al. Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology. Blood Adv. 2026;10:320–33. https://doi.org/10.1182/bloodadvances.2025017282.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, et al. High cure rates in Burkitt lymphoma and leukemia: A Northern Italy leukemia group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013;98:1718–25. https://doi.org/10.3324/haematol.2013.086827.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–9. https://doi.org/10.1182/blood.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, et al. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol. 2013;88:1062–7. https://doi.org/10.1002/ajh.23566.

    Article  PubMed  Google Scholar 

  10. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165:102–11. https://doi.org/10.1111/bjh.12736.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ferreri AJM, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, et al. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. Blood Adv Am Soc Hematol. 2022;6:2578–80. https://doi.org/10.1182/bloodadvances.2022007475.

    Article  Google Scholar 

  12. Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol. 2012;156:234–44. https://doi.org/10.1111/j.1365-2141.2011.08947.x.

    Article  PubMed  Google Scholar 

  13. Minson A, Verner E, Giri P, Butler J, Janowski W, Cheah CY, et al. Glofitamab Combined with Pola-R-CHP or R-CHOP as First Therapy in Younger Patients with High-Risk Large B-Cell Lymphoma: Results from the COALITION Study. J Clin Oncol. 2025;43:2595–605. https://doi.org/10.1200/JCO-25-00481.

    Article  PubMed  Google Scholar 

  14. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386:351–63. https://doi.org/10.1056/nejmoa2115304.

    Article  PubMed  Google Scholar 

  15. Westin J, Chavez J, Schuster SJ, Vucinic V, Young PA, et al. Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results. Blood. 2025;146:670–670. https://doi.org/10.1182/blood-2025-670.

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Associazione Italiana Ricerca contro il Cancro. AIRC 5 × 1000 Immunity in Cancer Spreading and Metastasis (grant 21147) to AR and Associazione Italiana Lotta alla Leucemia, Linfoma e Mieloma (AIL) sezione Paolo Belli Bergamo.

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

    Silvia Ferrari, Francesco Ballardini, Andrea Rossi, Anna Grassi, Chiara Pavoni, Giuseppe Gritti, Anna Maria Barbui, Federico Lussana & Alessandro Rambaldi

  2. Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy

    Monica Rondi

  3. Department of Pathology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

    Paolo Fruscella & Andrea Gianatti

  4. Department of Oncology and Hematology, University of Milan, Milan, Italy

    Federico Lussana & Alessandro Rambaldi

  5. Foundation for Clinical Research Ospedale di Bergamo-FROM, Bergamo, Italy

    Alessandro Rambaldi

Authors

  1. Silvia Ferrari
  2. Francesco Ballardini
  3. Andrea Rossi
  4. Anna Grassi
  5. Chiara Pavoni
  6. Monica Rondi
  7. Paolo Fruscella
  8. Andrea Gianatti
  9. Giuseppe Gritti
  10. Anna Maria Barbui
  11. Federico Lussana
  12. Alessandro Rambaldi

Contributions

A.R conceived and designed the study. S.F. collected and assembled the data. C.P. analyzed the data. S.F and F.B wrote the manuscript. All authors reviewed and revised the manuscript, approved the final version, and agreed to submit the manuscript for publication.

Corresponding author

Correspondence to Alessandro Rambaldi.

Ethics declarations

Competing interests

Alessandro Rambaldi. Consulting: Amgen, Otsuka, Sanofi, Italfarmaco, Incyte, menarini, Stemline, Omeros, Kite-Gilead. Patients and Royalties: Italfarmaco. Silvia Ferrari. Consulting or Advisory Role: Incyte, BeiOne, Takeda. Travel, Accommodations, Expenses: Astrazeneca, BeiOne, Johnson & Johnson/Janssen. Francesco Ballardini. Advisory Role: Abbvie. Giuseppe Gritti. Advisory board: Abbvie, AstraZeneca, BMS, Genmab, Ideogen, Kite-Gilead, Roche, Takeda, Speaker’s bureau: Genmab, Roche, Ideogen. Research support: Ideogen. Other: J&J, Kite-Gilead, BeOne (support for attending meetings) Anna Maria Barbui. Speakers Bureau and Advisory Role: Incyte. Advisory Role: Bristol Myers Squibb, Pierre Fabre, Gentili. Travel, Accommodations, Expenses: Abbvie, Astrazeneca, Takeda, Novartis, Gilead, Johnson & Johnson/Janssen. Andrea Gianatti, Paolo Fruscella, Monica Rondi, Chiara Pavoni, Anna Grassi. No COI. Federico Lussana. Speakers Bureau and Advisory Role: Amgen, Abbvie. Speakers Bureau: Pfizer, Incyte, Astellas, Jazz Pharmaceuticals. Advisory Role: Clinigen.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrari, S., Ballardini, F., Rossi, A. et al. The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma. Blood Cancer J. 16, 176 (2026). https://doi.org/10.1038/s41408-026-01630-8

Download citation

  • Received: 14 May 2026

  • Accepted: 14 September 2026

  • Published: 09 October 2026

  • Version of record: 09 October 2026

  • DOI: https://doi.org/10.1038/s41408-026-01630-8

来源:Nature 健康护理主题 · nature.com